Coronavirus (COVID-19) updates for UC San Diego Health patients and visitors. Learn More

Menu
Search

City of Hope Gives von Gunten Humanitarian Award

 

January 28, 2008  |  

Charles von Gunten, M.D., Ph.D., Associate Clinical Professor of Medicine at UCSD, is the 2007 recipient of the Sarnat Distinguished Humanitarian Award, given by the City of Hope Comprehensive Cancer Center in recognition of outstanding scientific and humanitarian achievement in hospice and palliative care. 

Charles von Gunten, M.D., Ph. D.

Charles von Gunten, M.D., Ph. D.

Von Gunten is a member of the Moores UCSD Cancer Center, and medical director of the Doris A. Howell Service, a clinical consultation service for palliative and supportive care, which is based at the Cancer Center. He holds an established investigator award from the National Cancer Institute and is editor-in-chief of the Journal of Palliative Medicine. He also holds the position of Provost of the Center for Palliative Studies at San Diego Hospice & Palliative Care, which sponsors the largest fellowship program in palliative medicine in the U.S.  

This is the 12th year the Sarnat award has been given by the City of Hope Comprehensive Cancer Center in Duarte, California.

###

Media Contact: Nancy Stringer, 619-543-6163, nstringer@ucsd.edu


Related Specialties

UCSD Moores Cancer Center


Media Contact

Share This Article


Related News

5/26/2020
UC San Diego Health has deployed a mobile ECMO life support system to help sustain critically-ill patients during the pandemic.
5/21/2020
During COVID-19, UC San Diego Health expanded telehealth to provide patients with safe and convenient access to appointments with their health care providers. Video visits expanded by more than 50-fol ...
5/19/2020
UC San Diego researchers have identified small molecules in the blood of asymptomatic pregnant women that may predict risk for preeclampsia, responsible for a significant proportion of maternal and ne ...
5/15/2020
The NIH has launched a major clinical trial to assess the malaria drug hydroxychloroquine and antibiotic azithromycin as a treatment for COVID-19. The trial will recruit 2,000 participants at 30 sites ...



Follow Us